Eli Lilly and Company
https://www.lilly.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Eli Lilly and Company
Deals In Bag, Dr Reddy’s Sharpens Top 5 Targeted Home Run
Dr Reddy’s shapes journey to the top 5 league on home turf, backed by a string of deals with big pharma to bridge portfolio gaps and supplement its base business. Can they deliver impactful gains in the competitive Indian market?
'Future Fit' Cipla: Play In Oligonucleotides, Obesity Amid Promoter Stake Action
Cipla is stepping into the oligonucleotides space, where it also hopes to help shape the regulatory environment. Action is also anticipated in ‘big, identified areas’ such as obesity that may see potential partnering opportunities with Eli Lilly, with which the Indian firm has an existing alliance for diabetes therapies.
Lilly’s Weekly Insulin Efsitora Hits Mark In Two Trials, With Three More To Go
The QWINT-2 and QWINT-4 trials showed non-inferiority to daily insulin, but efsitora will likely hit the market sometime after competitor Novo Nordisk’s Awiqli.
Roche’s New Obesity Play Shows Early Promise
CT-388 hits in Phase I, but there is a long way to go before the Carmot acquisition pays off.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Akouos, Inc.
- Alnara Pharmaceuticals, Inc.
- ARMO BioSciences, Inc.
- Applied Molecular Evolution
- Avid Radiopharmaceuticals, Inc.
- Bowfin Acquisition Corporation
- Class AP
- CoLucid Pharmaceuticals, Inc.
- Dermira Inc.
- Disarm Therapeutics, Inc.
- Hypnion
- ICOS Corporation
- ImClone Systems
- Loxo Oncology, Inc. (LOXO)
- Protomer Technologies
- SGX Pharmaceuticals (Structural GenomiX)
- Valocor Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice